Atlas Genetics Aims to Market POC MDx Platform, First Test for Chlamydia, by End of 2014 | GenomeWeb

Atlas Genetics, a UK-based firm specializing in point-of-care in vitro diagnostics, is aiming to market its first products — a low-cost, ultra-rapid, cartridge-based testing system and associated nucleic acid test for Chlamydia trachomatis — with CE marking by the end of 2014, a company representative said recently.

Soon thereafter, Atlas aims to then commercialize a combined chlamydia/gonorrhea molecular assay both in Europe and the US, followed by tests for Trichomonas vaginalis, herpes simplex virus, syphilis, and HIV.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.